Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systematically individualizing tobramycin dosage regimens

R J Cipolle, R D Seifert, D E Zaske

    Journal of Clinical Pharmacology
    |October 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Predictors of intracranial pathologic findings in patients who seek emergency care because of headache.

    Archives of neurology·1997
    Same author

    A retrospective study of sodium nitroprusside use and assessment of the potential risk of cyanide poisoning.

    Pharmacotherapy·1995
    Same author

    Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics.

    Clinical pharmacology and therapeutics·1995
    Same author

    Anti-infective agents and hepatic disease.

    The Medical clinics of North America·1995
    Same author

    Q and A from the Pharmaceutical Care Project in Minnesota.

    American pharmacy·1995
    Same author

    The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in Alzheimer's disease.

    Progress in neuro-psychopharmacology & biological psychiatry·1995
    Same journal

    Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

    Journal of clinical pharmacology·2026
    Same journal

    New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

    Journal of clinical pharmacology·2026
    Same journal

    Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

    Journal of clinical pharmacology·2026
    Same journal

    The Journal of Clinical Pharmacology: 65 Years of History.

    Journal of clinical pharmacology·2026
    Same journal

    Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

    Journal of clinical pharmacology·2026
    Same journal

    Mind the Gap: Unraveling the Pharmacokinetic Variability of Δ9-Tetrahydrocannabinol (THC).

    Journal of clinical pharmacology·2026
    See all related articles

    Individual tobramycin dosing is crucial due to wide patient variations in pharmacokinetics. Tailored regimens achieved therapeutic serum concentrations, avoiding toxicity in patients.

    Area of Science:

    • Pharmacology and Therapeutics
    • Clinical Pharmacy

    Background:

    • Tobramycin dosing commonly relies on standard guidelines.
    • Significant interpatient variability exists in tobramycin pharmacokinetics.
    • Standard dosing may not achieve optimal therapeutic drug concentrations.

    Purpose of the Study:

    • To evaluate individualized tobramycin dosage regimens.
    • To assess the achievement of target serum concentrations.
    • To determine the success of a pharmacokinetic model in optimizing tobramycin therapy.

    Main Methods:

    • Serum concentration-time data analyzed for 64 patients.
    • Individual tobramycin pharmacokinetic parameters calculated.
    • Multiple regression analysis used to identify factors influencing clearance.

    Related Experiment Videos

    Main Results:

    • Wide interpatient variability observed in tobramycin half-life and distribution volume.
    • Dosage requirements varied significantly, particularly with age.
    • Individualized regimens achieved desired peak (7.1 µg/ml) and trough (1.3 µg/ml) concentrations.
    • No ototoxicity or nephrotoxicity observed despite higher-than-recommended doses in some patients.

    Conclusions:

    • Individualized tobramycin dosing is essential for optimizing therapeutic outcomes.
    • Pharmacokinetic modeling successfully guided dosage adjustments.
    • This approach can achieve target concentrations safely and effectively.